A new treatment for psoriatic arthritis, a painful disease that affects the joints, skin, and tendons, has delivered promising early results in an international clinical trial.
More than 200 people from around the world took part in this study, and many experienced major relief from symptoms that previously controlled their daily lives.
Psoriatic arthritis, often called PsA, is a long-lasting autoimmune condition. It causes swelling, stiffness, and inflammation in joints, making even simple movements painful. The disease can also cause red, scaly patches on the skin.
Over a million people in Europe alone are estimated to have PsA, and many of them do not respond well to current treatments. Living with the condition can be extremely draining, both physically and emotionally.
In a new study published in Nature Medicine, researchers tested a new type of medicine called sonelokimab. This medicine is a “nanobody,” which means it is much smaller than normal antibodies—only about one-third the size.
Because of its tiny structure, it may be able to travel more easily into swollen, inflamed tissue where it can block the proteins that cause inflammation.
Sonelokimab was developed by MoonLake Immunotherapeutics and is the first nanobody ever tested in psoriatic arthritis.
The medicine works by blocking two important proteins, IL‑17A and IL‑17F, which are known to drive inflammation in PsA. By stopping these proteins, the drug can help calm the immune system and reduce swelling, pain, and skin irritation.
The results of the clinical trial were encouraging. After 24 weeks—about six months—more than half of the patients who took sonelokimab showed major improvements in their joint symptoms. Many participants also saw their skin symptoms almost completely disappear, something that can significantly improve confidence and quality of life.
The benefits extended beyond pain relief. Up to 60% of patients reached what doctors call “minimal disease activity.” This means their symptoms became so mild that they barely interfered with daily life. Patients also reported better mobility, reduced stiffness, improved mood, and higher overall life satisfaction.
Importantly, the treatment was well tolerated. Most side effects were mild, and no serious safety concerns were reported. This is especially meaningful for people who cannot tolerate current treatments or have not seen good results from them.
Professor Iain McInnes from the University of Glasgow, who led the global research team, said he was thrilled by the results. He explained that the next step is to run larger trials in Europe and the United States to confirm how well the medicine works across diverse patient groups.
Reviewing the study, the findings suggest several important points. First, sonelokimab may offer a new and highly effective option for people who struggle with psoriatic arthritis.
Current treatments do not work for everyone, and many lose effectiveness over time. A medicine that can more effectively reach inflamed tissues and block two key inflammatory proteins could mark a major shift in treatment.
Second, the strong improvement in both joint and skin symptoms shows how powerful dual‑target nanobodies may be. While early, the results indicate that this class of medicines may outperform some existing therapies, especially for patients with severe symptoms.
Third, the safety profile is encouraging. A treatment that is both effective and well tolerated is extremely valuable in long‑term conditions like PsA, where patients must often stay on medication for many years.
Finally, the trial highlights the growing potential of nanobody technology. Because nanobodies are small and flexible, they may be able to treat diseases that traditional antibodies cannot reach as easily.
Overall, this early research provides real hope for millions of people living with psoriatic arthritis. If future trials confirm these results, sonelokimab could become a major new treatment option, offering faster relief, fewer symptoms, and a better quality of life.
If you care about pain, please read studies about how to manage gout with a low-purine diet, and a guide to eating right for arthritis.
For more health information, please see recent studies about the link between processed foods and chronic diseases, and avoid these 8 foods to ease arthritis pain.
Copyright © 2025 Knowridge Science Report. All rights reserved.
